Ligand Pharmaceuticals Incorporated Stock News

The consensus price target hints at a 44.3% upside potential for Ligand (LGND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND

Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Ligand Pharmaceuticals (LGND) and Illumina (ILMN). But which of these two companies is the best opti

Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.

Although investors can bag profits by following the masses, it's also possible to accrue substantive rewards by walking the path least traveled with top stocks for smart investors. That's not to say t

The mean of analysts' price targets for Ligand (LGND) points to a 44.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

IDCC, TMHC, NXT, GRBK and LGND are five stocks with explosive relative price strength.

Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.

The mean of analysts' price targets for Ligand (LGND) points to a 38.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

VREX, LGND, RNGR, SIGA and KMT have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2023.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2023 Results Conference Call May 4, 2023 4:30 PM ET Company Participants Simon Latimer - Head of Investor Relations Todd Davis - Chief Executive O

Ligand Pharmaceuticals (LGND) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.58 per share a year ago.

Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Ligand Pharmaceuticals (LGND) and Regeneron (REGN). But which of these two stocks presents investors with the